Stock Events

Stock Events

Paradigm Biopharmaceuticals Limited 

€0
0
-€0.13-100% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26FebExpected
Q4 2025
-0.03
0.3
0.63
0.97
Expected EPS
N/A
Actual EPS
-0.031774033974

People Also Follow

This list is based on the watchlists of people on Stock Events who follow P86.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, including those in the biopharmaceutical field similar to Paradigm's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals competes in the biopharmaceutical sector, particularly in developing innovative medicines for various diseases, overlapping with Paradigm's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a competitor due to its strong presence in the biopharmaceutical industry, focusing on antiviral drugs and other treatments that could compete with Paradigm's product offerings.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a competitor because of its broad focus on biotechnological medicines, including treatments for inflammatory diseases, which may overlap with Paradigm's research and development efforts.
Biogen
BIIB
Mkt Cap26.03B
Biogen competes with Paradigm in the biopharmaceutical space, especially in the development of therapies for neurological and neurodegenerative diseases.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie is a competitor as it operates in the biopharmaceutical sector with a strong emphasis on research and development in areas that could intersect with Paradigm's interests, such as autoimmune diseases.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a global pharmaceutical company with a wide range of products that could compete with Paradigm's treatments, especially in the biopharmaceutical and vaccine sectors.
Merck
MRK
Mkt Cap298.84B
Merck & Co. is a competitor because of its extensive research and development in pharmaceuticals that could directly compete with Paradigm's therapeutic areas, including infectious diseases and oncology.
Novartis
NVS
Mkt Cap297.32B
Novartis is a competitor due to its significant investment in research and development in the healthcare sector, including areas that overlap with Paradigm's focus, such as chronic diseases.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca is a competitor because it operates broadly in the biopharmaceutical sector, focusing on various therapeutic areas, including respiratory, cardiovascular, and autoimmune diseases, which may compete with Paradigm's portfolio.

About

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Show more...
CEO
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC
Country
United States
ISIN
AU000000PAR5

Listings

F
DE
P86.F
AU
AU
PAR.AU
STU
DE
P86.STU
OTC Link
US
PBIGF

0 Comments

Share your thoughts

FAQ

What is Paradigm Biopharmaceuticals Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Paradigm Biopharmaceuticals Limited stocks are traded under the ticker P86.STU.
Is Paradigm Biopharmaceuticals Limited stock price growing?▼
P86.STU stock has fallen by -12.5% compared to the previous week, the month change is a -13.64% fall, over the last year Paradigm Biopharmaceuticals Limited has showed a -13.64% decrease.
When is the next Paradigm Biopharmaceuticals Limited earnings date?▼
Paradigm Biopharmaceuticals Limited is going to release the next earnings report on August 21, 2026.
What were Paradigm Biopharmaceuticals Limited earnings last quarter?▼
P86.STU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Paradigm Biopharmaceuticals Limited located?▼
Paradigm Biopharmaceuticals Limited operates in the Health & Wellness sector.
When did Paradigm Biopharmaceuticals Limited complete a stock split?▼
Paradigm Biopharmaceuticals Limited has not had any recent stock splits.
Where is Paradigm Biopharmaceuticals Limited headquartered?▼
Paradigm Biopharmaceuticals Limited is headquartered in Melbourne, United States.